EXHIBIT 10.1
------------
======================================================================
STAND-BY PURCHASE AGREEMENT
BETWEEN
RAMIUS CAPITAL GROUP, LLC
AND
MGI PHARMA, INC.
FEBRUARY 28, 2001
=====================================================================
FUEL(TM) PATENT PENDING
TABLE OF CONTENTS
-----------------
Page
----
I. DEFINITIONS..................................................................................... 1
II. PURCHASE AND SALE OF COMMON STOCK............................................................... 2
2.1 Investments............................................................................. 2
2.2 Limitations on Investment Amount........................................................ 2
2.3 Closings and Settlements................................................................ 2
2.4 Termination, Suspension and Modification of Investment Obligation....................... 3
III. CONDITIONS PRECEDENT............................................................................ 3
3.1 Conditions Precedent to the Obligation of the Investor to Purchase Common Stock
Pursuant to a Demand Notice........................................................ 3
3.2 Occurrence of Material Events........................................................... 3
3.3 Due Diligence Review.................................................................... 4
IV. REPRESENTATIONS AND WARRANTIES OF INVESTOR...................................................... 4
4.1 Authorization; Enforcement.............................................................. 4
4.2 Not an Affiliate........................................................................ 4
4.3 Organization and Standing............................................................... 4
4.4 Absence of Conflicts.................................................................... 5
4.5 Compliance with Securities Laws......................................................... 5
V. REPRESENTATIONS AND WARRANTIES OF THE COMPANY................................................... 5
5.1 Representations and Warranties Incorporated By Reference................................ 5
VI. COVENANTS....................................................................................... 5
6.1 Covenants Incorporated By Reference..................................................... 5
6.2 Short Selling........................................................................... 5
VII. ASSIGNMENT, ENTIRE AGREEMENT, AMENDMENT, TERMINATION............................................ 5
7.1 Successors and Assigns.................................................................. 5
7.2 Entire Agreement; Amendment............................................................. 6
7.3 Publicity............................................................................... 6
7.4 Termination............................................................................. 6
VIII.NOTICES; COSTS AND EXPENSES..................................................................... 8
8.1 Notices................................................................................. 8
8.2 Costs and Expenses...................................................................... 9
IX. INDEMNIFICATION AND CONTRIBUTION................................................................ 9
9.1 Indemnification......................................................................... 9
9.2 Contribution............................................................................ 11
i
FUEL(TM) PATENT PENDING
Page
----
X. GOVERNING LAW; MISCELLANEOUS..................................................................... 11
10.1 Governing Law........................................................................... 11
10.2 Counterparts............................................................................ 11
10.3 Headings................................................................................ 12
10.4 Severability............................................................................ 12
10.5 Survival................................................................................ 12
10.6 No Third Party Beneficiaries............................................................ 12
10.7 Further Assurances...................................................................... 12
10.8 Construction............................................................................ 12
10.9 Equitable Relief........................................................................ 12
10.10 Consent to Jurisdiction................................................................ 13
ii
FUEL(TM) PATENT PENDING
CROSS REFERENCES
----------------
Defined Term
------------
"Agreement" Preamble
"Blocking Event" Section 2.4
"Claims" Section 9.1(a)
"Closing Date" Section 1
"Common Stock" Recitals
"Company" Preamble
"Condition Precedent Date" Section 3.1
"DTC" Section 2.3(a)
"Indemnified Damages" Section 9.1(a)
"Indemnified Party" Section 9.1(b)
"Indemnified Person" Section 9.1(a)
"Investor" Preamble
"Notice of Blocking Period" Section 3.2
"Notification Date" Section 1
"Permitted Transferee" Section 7.1
"Purchase Price" Section 1
"Registrable Securities" Section 1
"Registration Statement" Section 2.4(a)(i)
"SEC" Section 2.4
"Settlement" Section 2.3(a)
"Settlement Date" Section 1
"Underwriter" Recitals
"Underwriting Agreement" Recitals
"Violations" Section 9.1(a)
FUEL(TM) PATENT PENDING
STAND-BY PURCHASE AGREEMENT
---------------------------
STAND-BY PURCHASE AGREEMENT dated as of February 28, 2001 (the
"Agreement"), between Ramius Capital Group, LLC, a limited liability company
organized and existing under the laws of the State of Delaware (the "Investor"),
and MGI PHARMA, Inc., a corporation organized and existing under the laws of the
State of Minnesota (the "Company").
W I T N E S S E T H :
WHEREAS, pursuant to the Common Stock Underwriting Agreement between
Ramius Securities, LLC (the "Underwriter") and the Company dated as of the date
hereof (the "Underwriting Agreement"), the Underwriter agreed to sell, as the
Company's agent, on a best efforts basis, up to $100 million of the Company's
Common Stock, $.01 par value per share (the "Common Stock");
WHEREAS, upon the terms and subject to the conditions of this
Agreement, should the Underwriter fail to fulfill its Selling Period Obligation
then the Investor shall be obligated to purchase the number of shares of the
Company's Common Stock necessary to fulfill the Underwriter's Selling Period
Obligation.
NOW, THEREFORE, the parties hereto agree as follows:
I. DEFINITIONS.
-----------
Capitalized terms not defined herein shall have the same meaning
ascribed to them in the Underwriting Agreement. As used in this Agreement, the
following terms shall have the following meanings:
"Closing Date" shall mean, with respect to the purchase and sale of
Common Stock subject to the conditions contained herein, the first Trading Day
following the expiration of the Selling Period if the Underwriter fails to
fulfill its Selling Period Obligation for such Selling Period.
"Purchase Price" shall mean 96% of the VWAP for the first Trading Day
following the expiration of the Selling Period; provided, that if the VWAP for
such Trading Day is at or below the Floor Price, the VWAP for such day shall be
deemed to be the Floor Price.
"Registrable Securities" shall mean any shares of Common Stock issued
or issuable to the Investor or any holder or transferee pursuant to this
Agreement and any shares of Capital Stock issued or issuable with respect to the
foregoing as a result of any stock split, stock dividend, recapitalization,
exchange or similar event.
"Registration Statement" shall mean a registration statement
of the Company, as amended or supplemented from time to time, relating to (i)
Common Stock issuable pursuant to the Underwriting Agreement (including shares
of Common Stock issuable in connection with the exercise of the Purchase Option)
and (ii) Common Stock issuable pursuant to this Agreement.
"Settlement Date" shall mean, with respect to the purchase and sale of
Common Stock, subject to the conditions contained herein, the Trading Day no
later than three days (or such lesser time period as is mandated under "regular
ways" settlement on the Principal Market) following the Closing Date.
FUEL(TM) PATENT PENDING
II. PURCHASE AND SALE OF COMMON STOCK.
---------------------------------
2.1 Investments. If pursuant to the terms and conditions of the
Underwriting Agreement, the Company delivers a Demand Notice to the Underwriter
and the Underwriter fails to fulfill its Selling Period Obligation, then the
Investor, subject to the terms and conditions of this Agreement, shall be
obligated to purchase from the Company the number of shares of Common Stock
necessary to fulfill the Underwriter's Selling Period Obligation.
2.2 Limitations on Investment Amount.
--------------------------------
(a) Selling Period Obligation. The Investor's obligation to purchase
shares of the Company's Common Stock shall be null and void if (i) a Blocking
Event occurs (as provided in Section 2.4); or (ii) the remaining Selling Period
Obligation multiplied by the Purchase Price is less than $100,000. The Investor
may waive, in its sole discretion, in whole or in part, the limitations on the
Investor's obligations to purchase shares of Common Stock contained in this
Section 2.2(a).
(b) 4.9% Limit. Notwithstanding anything herein to the contrary, the
Investor shall not be required nor allowed to purchase, and the Company shall
not issue, shares of Common Stock pursuant to this Agreement on the Closing Date
to the extent such purchase, when aggregated with all other shares of Common
Stock then beneficially owned by the Investor, would result in the Investor or
any Affiliate of the Investor beneficially owning more than 4.9% of all the
issued and outstanding Common Stock of the Company on such Closing Date. For
purposes of this Agreement, beneficial ownership shall be calculated in
accordance with Section 13(d) of the Exchange Act.
2.3 Closings and Settlements.
------------------------
(a) Deliveries. On the Settlement Date (i) the Company shall credit
such aggregate number of shares of Common Stock that the Investor had purchased
on the Closing Date to the Investor's or its designee's balance account with The
Depository Trust Company ("DTC") through its Deposit and Withdrawal At Custodian
system or deliver such shares by such other means as may be mutually agreed by
the parties; and (ii) if such shares are so received no later than 1:00 p.m.
Eastern time, the Investor shall deliver to the Company's brokerage account at
the Underwriter, (or if later than 1:00 p.m. Eastern time, in funds available
the next Trading Day) on or prior to the Settlement Date, a dollar amount equal
to (A) the number of shares so received multiplied by (B) the Purchase Price. In
addition, prior to the Closing Date, each of the Company and the Investor shall
deliver all documents, instruments and writings required to be delivered or
reasonably requested by either of them pursuant to this Agreement in order to
implement and effect the transactions contemplated herein.
(b) Company's Failure to Deliver Shares. If the Company shall fail to
deliver the shares of Common Stock to the Investor by the Settlement Date, the
Investor shall send a written notice to the Company advising the Company that
such shares have not been received. If, after such notice, the Company shall
fail to issue the shares of Common Stock by the fifth Business Day after the
Settlement Date for such shares, the Company shall pay damages to the Investor
equal to any actual damages incurred by the Investor because of the Company's
failure to deliver such required shares, including damages resulting from the
Investor's need, as determined by the Investor in its sole discretion, (A) to
"unwind" any and all sales of the Company's Common Stock made by the Investor
and to reimburse any and all purchasers for their completed purchases of the
Company's Common Stock and (B) to "buy in" shares of Common Stock to the extent
necessary to satisfy its securities delivery requirements. Moreover, if the
shares have not been delivered by such date, the Investor will not be obligated
to pay the Company (unless the Company has already paid the Investor's actual
damages, if any, incurred during such Selling
2
FUEL(TM) PATENT PENDING
Period) for any shares purchased by the Investor or that the Investor agreed to
purchase or was obligated to purchase during the Selling Period. In addition, if
the shares have not been delivered by the Company by the fifth Business Day
after the Settlement Date, at the Investor's sole option, it may terminate this
Agreement.
2.4 Termination, Suspension and Modification of Investment Obligation.
-----------------------------------------------------------------
(a) Blocking Events. The Investor shall not be obligated to purchase
any shares of Common Stock from the Company when there shall exist any one or
more of the following:
(i) the withdrawal or suspension of the effectiveness of a
registration statement (the "Registration Statement") for the registration of
not less than the number of shares of Common Stock equal to Maximum Offering
Amount divided by the Floor Price, which Registration Statement shall have been
declared effective by the Securities and Exchange Commission (the "SEC");
(ii) the failure of the Common Stock issuable hereunder to be
validly listed on the Principal Market;
(iii) the Company's failure to satisfy the requirements of
Section 3.1 or 3.3;
(iv) any failure or interruption in the compliance by the
Company with any of the covenants provided in Article VI;
(v) any merger or consolidation of the Company with or into, or
a transfer of all or substantially all of the assets of the Company to, another
entity; or
(vi) receipt or Deemed Receipt (as provided in Section 3.2) by
the Investor of a Notice of Blocking Period (each of (i), (ii), (iii), (iv), (v)
or (vi), a "Blocking Event").
(b) The Company shall be obligated to notify the Investor in writing
using the form attached hereto as Exhibit 3.2 immediately upon the occurrence of
a Blocking Event. The Investor shall be entitled, in its sole discretion, to
waive any Blocking Event in writing.
III. CONDITIONS PRECEDENT.
--------------------
3.1 Conditions Precedent to the Obligation of the Investor to
Purchase Common Stock Pursuant to a Demand Notice. The obligation of the
Investor to purchase Common Stock and to acquire and pay for Common Stock on the
Closing Date is subject to the satisfaction on the Closing Date (the "Condition
Precedent Date") of the conditions precedent set forth in Section 3.1 of the
Underwriting Agreement (other than the conditions set forth in Subsections
3.1(l) and 3.1(n)), which conditions are incorporated by reference herein as if
fully set forth in this Agreement as of the date hereof and which cannot be
waived without the prior written consent of the Investor; provided, that (i) if
any terms are defined in both the Underwriting Agreement and this Agreement, the
defined terms in this Agreement shall govern, (ii) any reference to Common Stock
to be issued pursuant to the Underwriting Agreement shall hereby refer to Common
Stock issuable pursuant to this Agreement, (iii) any reference to the
Underwriter shall hereby refer to the Investor, unless the context dictates
otherwise and (iv) any reference to the Underwriting Agreement shall hereby
refer to this Agreement, unless the context dictates otherwise.
3.2 Occurrence of Material Events. If the Company's management
determines in its good faith judgment (i) that it is required or advisable to do
so or (ii) that any fact exists or any event has
3
FUEL(TM) PATENT PENDING
occurred that makes any statement of a material fact made in the Registration
Statement, the prospectus, any amendment or supplement thereto, or any document
incorporated by reference therein untrue in any material respect, or that
requires the making of any additions to or changes in the Registration Statement
or the prospectus, in order to make the statements therein not misleading in any
material respect, the Company shall notify the Investor using the form attached
hereto as Exhibit 3.2 (a "Notice of Blocking Period") that it may not sell the
Registrable Securities pursuant to any Registration Statement or prospectus;
provided, that if the Investor reasonably believes, after consultation with its
attorneys and with the Company and after notice to the Company, that a fact
exists or an event has occurred that makes any statement of a material fact made
in the Registration Statement, the prospectus, any amendment or supplement
thereto, or any document incorporated by reference therein untrue in any
material respect, or that requires the making of any additions to or changes in
the Registration Statement or the prospectus, in order to make the statements
therein not misleading in any material respect, then the Company shall have been
deemed to have delivered a Notice of Blocking Period to the Investor. The
Investor agrees that, upon receipt of a Notice of Blocking Period from the
Company of the existence of any fact of the kind described in the immediately
preceding sentence, the Investor shall not dispose of, sell or offer for sale
the Registrable Securities pursuant to the Registration Statement until such
Investor receives (i) copies of the supplemented or amended prospectus, unless
counsel for the Company shall have determined that such disclosure is not
required due to subsequent events, (ii) notice in writing from the Company that
the use of the prospectus may be resumed and (iii) copies of any additional or
supplemental filings that are incorporated by reference in the Prospectus. If so
directed by the Company in connection with any such notice, the Investor will
deliver to the Company (at the Company's expense) all copies, other than
permanent file copies then in such Investor's possession, of the prospectus
covering such Registrable Securities that was current immediately prior to the
time of receipt of such notice.
3.3 Due Diligence Review. The Investor shall be entitled to rely
on and have the benefits of the due diligence review conducted by the
Underwriter pursuant to Section 3.2 of the Underwriting Agreement.
IV. REPRESENTATIONS AND WARRANTIES OF INVESTOR.
------------------------------------------
The Investor represents and warrants to the Company as follows:
4.1 Authorization; Enforcement. The Investor has full power and
authority to execute and deliver this Agreement, and to consummate the
transactions contemplated hereby in accordance with the terms hereof. The
execution and delivery of this Agreement and the consummation of the
transactions contemplated hereby have been duly authorized by the Investor. No
other proceedings on the part of Investor are necessary to approve and authorize
the execution and delivery of this Agreement and the consummation of the
transactions contemplated hereby in accordance with the terms hereof. This
Agreement has been validly executed and delivered by the Investor and is a valid
and binding agreement of the Investor enforceable against it in accordance with
its terms, subject as to enforceability to general principles of equity and to
applicable bankruptcy, insolvency, reorganization, moratorium, liquidation and
similar laws relating to, or affecting generally the enforcement of, applicable
creditors' rights and remedies.
4.2 Not an Affiliate. The Investor is not an officer, director or
Affiliate of the Company.
4.3 Organization and Standing. The Investor is duly organized,
validly existing, and in good standing under the laws of Delaware, and has all
requisite power and authority to carry on its business as now being conducted,
and is duly qualified to do business and in good standing in each
4
FUEL(TM) PATENT PENDING
jurisdiction in which the nature of the business conducted by it makes such
qualifications necessary, except where the failure to be so qualified or in good
standing would not have a material adverse effect.
4.4 Absence of Conflicts. The execution and delivery of this
Agreement and any other document or instrument executed in connection herewith,
and the consummation of the transactions contemplated hereby and thereby, and
compliance with the requirements hereof and thereof, will not violate the
provision of any indenture, instrument or agreement to which the Investor is a
party or is subject, or by which the Investor or any of its assets is bound, or
conflict with or constitute a material default thereunder, or result in the
creation or imposition of any lien pursuant to the terms of any such indenture,
instrument or agreement, or constitute a breach of any fiduciary duty owed by
the Investor to any third party.
4.5 Compliance with Securities Laws. To the Knowledge of the
Investor, any transactions in the Common Stock effected by the Investor pursuant
to this Agreement comply with all applicable securities laws and the rules and
regulations of the NASD.
V. REPRESENTATIONS AND WARRANTIES OF THE COMPANY.
---------------------------------------------
5.1 Representations and Warranties Incorporated By Reference. The
representations and warranties of the Company set forth in Article V of the
Underwriting Agreement are incorporated by reference herein as if fully set
forth in this Agreement as of the date hereof and are for the benefit of the
Investor; provided, that (i) if any terms are defined in both the Underwriting
Agreement and this Agreement, the defined terms in this Agreement shall govern,
(ii) any reference to Common Stock to be issued pursuant to the Underwriting
Agreement shall hereby refer to Common Stock issuable pursuant to this
Agreement, (iii) any reference to the Underwriter shall hereby refer to the
Investor, unless the context dictates otherwise and (iv) any reference to the
Underwriting Agreement shall hereby refer to this Agreement, unless the context
dictates otherwise.
VI. COVENANTS.
---------
6.1 Covenants Incorporated By Reference. In addition to the covenant
set forth below, the covenants set forth in Article VI of the Underwriting
Agreement are incorporated by reference herein as if fully set forth in this
Agreement as of the date hereof and are for the benefit of the Investor;
provided, that (i) if any terms are defined in both the Underwriting Agreement
and this Agreement, the defined terms in this Agreement shall govern, (ii) any
reference to Common Stock to be issued pursuant to the Underwriting Agreement
shall hereby refer to Common Stock issuable pursuant to this Agreement, (iii)
any reference to the Underwriter shall hereby refer to the Investor, unless the
context dictates otherwise and (iv) any reference to the Underwriting Agreement
shall hereby refer to this Agreement, unless the context dictates otherwise.
6.2 Short Selling. During the term of this Agreement, Investor and
its Affiliates shall not engage in any short selling activities with respect to
the Company's Common Stock.
VII. ASSIGNMENT, ENTIRE AGREEMENT, AMENDMENT, TERMINATION.
----------------------------------------------------
7.1 Successors and Assigns. Neither this Agreement nor any rights of
the Investor or the Company hereunder may be assigned by either party to any
other Person. Notwithstanding the foregoing, the Investor's rights and
obligations under this Agreement may be assigned at any time, in whole, with the
prior written consent of the Company (which consent shall not be unreasonably
withheld) to any Affiliate of the Investor (a "Permitted Transferee"). The
rights and obligations of the Investor
5
FUEL(TM) PATENT PENDING
under this Agreement shall inure to the benefit of, and be enforceable by and
against, any such Permitted Transferee.
7.2 Entire Agreement; Amendment. This Agreement, the Underwriting
Agreement and the other documents delivered pursuant hereto constitute the full
and entire understanding and agreement between the parties with regard to the
subjects hereof and thereof, and supercedes all other prior oral or written
agreements between the parties, their Affiliates, or persons acting on their
behalf. No party shall be liable or bound to any other party in any manner by
any warranties, representations or covenants except as specifically set forth in
this Agreement or therein. Except as expressly provided in this Agreement,
neither this Agreement nor any term hereof may be amended, waived, discharged or
terminated other than by a written instrument signed by the party against whom
enforcement of any such amendment, waiver, discharge or termination is sought.
7.3 Publicity. Each of the Company and the Investor agrees that they
will not make any disclosure to any Person, issue any press release or make any
other public announcement with respect to the terms hereof and the transactions
contemplated hereby without the prior consent of the other party, unless such
disclosure is required by law or applicable regulation or the listing
requirements of the Principal Market, and then only to the extent of such
requirement; provided, however, neither party may make any disclosure pursuant
to the listing requirements of the Principal Market without prior consultation
with the other party about its contents. Except as may be required by law or
applicable regulation, each of the Company and the Investor shall consult with
the other before issuing any press release or otherwise making any public
statements with respect to this Agreement and, except as required by law,
applicable regulation or the listing requirements of the Principal Market, shall
not issue any such press release or make any such public statement without the
prior written consent of the other party (which consent shall not be
unreasonably withheld).
7.4 Termination.
-----------
(a) The Company may, in its sole discretion, terminate the Investor's
obligation to purchase any Common Stock pursuant to Section 2.1; provided,
however, that such termination shall not affect the survival of (i)
representations and warranties pursuant to Articles IV and V, and
indemnification and contribution rights pursuant to Article IX, each as set
forth in Section 10.5, (ii) obligations relating to costs and expenses pursuant
to Section 8.2, (iv) obligations pursuant to Article II, to the extent such
termination shall occur at any time from the beginning of a Selling Period to
the Settlement Date, (v) covenants pursuant to Article VI (other than Section
6.11), to the extent any shares of Common Stock purchased by the Investor
pursuant to this Agreement are held by the Investor, (vi) the provisions of
Articles VII and X, or (vii) any other provisions of this Agreement that may be
reasonably construed to survive the termination of this Agreement.
(b) The Investor may (in its sole and absolute discretion) terminate
this Agreement and its obligation to purchase shares of Common Stock as a result
of (i) a breach by the Company of any material representation, warranty,
covenant or other obligation in connection with this Agreement, (ii) failure by
the Company to comply with the requirements of Section 6.2, 6.3, 6.4, 6.5 or 6.6
of the Underwriting Agreement (as the terms of such Sections are adjusted
pursuant to the provisos at the end of the first paragraph of Article VI of this
Agreement), (iii) the Company, at any date after the date hereof, effecting any
merger or consolidation of the Company with or into, or transferring all or
substantially all of the assets of the Company to, another entity or (iv) the
Investor reasonably determining, at any time that the adoption of, or change in,
or any change in the interpretation or application of, any law, regulation,
rule, guideline or treaty (including, but not limited to, laws, regulations,
rules or guidelines with respect to changes of capital adequacy) makes it
illegal or materially impracticable for the Investor to fulfill its commitment
pursuant to this Agreement, but in the case of (i) or (iv) above, the Investor
may
6
FUEL(TM) PATENT PENDING
terminate this Agreement only after a 30-day period beginning when the Investor
gives the Company notice of its intentions to terminate this Agreement (but the
Investor's right to terminate its obligation to purchase any shares of Common
Stock pursuant to a Demand Notice shall not be subject to any delay or
contingency), in which, in the case of (i), the Company has not cured such
breach as provided above, or, in the case of (iv), the parties negotiate in good
faith a reasonable alternative manner not illegal or impracticable for the
Investor to fulfill its commitment pursuant to this Agreement; provided,
however, that such termination shall not affect the survival of (i)
representations and warranties pursuant to Articles IV and V, and
indemnification and contribution rights pursuant to Article IX, each as set
forth in Section 10.5, (ii) obligations relating to costs and expenses pursuant
to Section 8.2, (iv) obligations pursuant to Article II, to the extent such
termination shall occur at any time from the beginning of a Selling Period to
the Settlement Date, (v) covenants pursuant to Article VI (other than Section
6.11), to the extent any shares of Common Stock purchased by the Investor
pursuant to this Agreement are held by the Investor, (vi) the provisions of
Articles VII and X, or (vii) any other provisions of this Agreement that may be
reasonably construed to survive the termination of this Agreement. If the
Company shall fail to comply with the requirements under Section 6.2, 6.3, 6.4,
6.5 or 6.6 of the Underwriting Agreement (as the terms of such Sections are
adjusted pursuant to the provisos at the end of the first paragraph of Article
VI of this Agreement) pursuant to clause (ii) above, the Company shall notify
the Investor within two (2) days of the time it becomes aware of the failure to
comply with any such covenants. If the Investor elects to terminate this
Agreement pursuant to clause (ii) above, it must first give the Company notice
of such election and may terminate this Agreement only after a 10-day period in
which the Company has not cured the failure to materially comply with any such
covenants; provided, however, that such termination shall not affect the
survival of (i) representations and warranties pursuant to Articles IV and V,
and indemnification and contribution rights pursuant to Article IX, each as set
forth in Section 10.5, (ii) obligations relating to costs and expenses pursuant
to Section 8.2, (iv) obligations pursuant to Article II, to the extent such
termination shall occur at any time from the beginning of a Selling Period to
the Settlement Date, (v) covenants pursuant to Article VI , to the extent any
shares of Common Stock purchased by the Investor pursuant to this Agreement are
held by the Investor, (vi) the provisions of Articles VII and X, or (vii) any
other provisions of this Agreement that may be reasonably construed to survive
the termination of this Agreement. The Investor may also, in its sole and
absolute discretion, terminate this Agreement if the Company shall fail to
maintain the listing of the Common Stock on a Principal Market, or if trading of
the Common Stock on a Principal Market shall have been suspended for a period of
ten (10) consecutive Trading Days; provided, however, that such termination
shall not affect the survival of (i) representations and warranties pursuant to
Articles IV and V, and indemnification and contribution rights pursuant to
Article IX, each as set forth in Section 10.5, (ii) obligations relating to
costs and expenses pursuant to Section 8.2, (iv) obligations pursuant to Article
II, to the extent such termination shall occur at any time from the beginning of
a Selling Period to the Settlement Date, (v) covenants pursuant to Article VI
(other than Section 6.11), to the extent any shares of Common Stock purchased by
the Investor pursuant to this Agreement are held by the Investor, (vi) the
provisions of Articles VII and X, or (vii) any other provisions of this
Agreement that may be reasonably construed to survive the termination of this
Agreement. The Investor may waive, in its sole and absolute discretion, in whole
or in part, any of the termination events contained in this Section 7.4.
(c) Upon the termination of the Underwriting Agreement pursuant to
Section 7.4 contained therein, this Agreement shall terminate; provided,
however, that such termination shall not affect the continuing obligations of
the parties hereto, as set forth in this Agreement, including the survival of
representations, warranties, covenants and indemnification rights of the
Investor.
7
FUEL(TM) PATENT PENDING
VIII. NOTICES; COSTS AND EXPENSES.
---------------------------
8.1 Notices. All notices, demands, requests, consents, approvals or
other communications required or permitted to be given hereunder or which are
given with respect to this Agreement shall be in writing and shall be (i)
personally served, (ii) deposited in the mail, registered or certified, return
receipt requested, postage prepaid, (iii) delivered by reputable air courier
service with charges prepaid, (iv) transmitted by hand delivery, or (v)
transmitted by facsimile, addressed as set forth below, or to such other address
as such party shall have specified most recently by written notice:
If to the Company, to:
MGI PHARMA, Inc.
▇▇▇▇ ▇▇▇▇ ▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇
▇▇▇▇▇ ▇▇▇
▇▇▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇
Attention: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇
Facsimile No.: (▇▇▇) ▇▇▇-▇▇▇▇
With a copy (which shall not constitute notice) to:
▇▇▇▇▇▇ & Whitney LLP
Pillsbury Center South
▇▇▇ ▇. ▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attention: ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇, Esq.
Facsimile No.: (▇▇▇) ▇▇▇-▇▇▇▇
If to the Investor, to
Ramius Capital Group, LLC
▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇/▇▇/ ▇▇▇▇▇
▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇
Attention: ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
Facsimile No.: (▇▇▇) ▇▇▇-▇▇▇▇
With a copy (which shall not constitute notice) to:
▇▇▇▇▇▇▇ ▇▇▇▇ & ▇▇▇▇▇ LLP
▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇
Attention: ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇, Esq.
Facsimile No.: (▇▇▇) ▇▇▇-▇▇▇▇
Any notice sent by one party to another with confirmation of
acceptance or otherwise received in writing via courier, hand delivery or first-
class mail (return receipt requested) by the Company, or, if received on any day
which is not a Trading Day or after 12:00 noon on a Trading Day, shall be deemed
to be delivered on the immediately succeeding Trading Day. Notice shall be
deemed given on the date of service or transmission if personally served or
transmitted by facsimile during normal business hours of the recipient;
provided, that such transmission by facsimile shall have been confirmed
received. Notice otherwise sent as provided herein shall be deemed given on the
third (3rd) business day
8
FUEL(TM) PATENT PENDING
following the date mailed or on the second business day following the date of
deposit for delivery of such notice with a reputable air courier service.
8.2 Costs and Expenses. In the event payment from the Company to the
Underwriter is not received within the thirty (30) day period set forth in
Section 8.2 of the Underwriting Agreement, Investor shall have the right to
deduct any such amounts owed by the Company to the Investor or the Underwriter
from any amounts owed by the Investor to the Company pursuant hereto; provided,
however, that Investor shall not exercise such right unless the Underwriter
acknowledges, to the Company, the discharge of the Company's obligation to the
Underwriter pursuant to such right of deduction by the Investor.
IX. INDEMNIFICATION AND CONTRIBUTION.
--------------------------------
9.1 Indemnification.
---------------
(a) To the fullest extent permitted by law, the Company will, and
hereby does, indemnify, hold harmless and defend the Investor, the directors,
officers, partners, employees and agents of the Investor and each Person, if
any, who controls any Investor within the meaning of the Securities Act or the
Exchange Act (each, an "Indemnified Person"), against any losses, claims,
damages, liabilities, judgments, fines, penalties, charges, costs, attorneys'
fees, amounts paid in settlement or expenses, joint or several (collectively,
"Claims"), incurred in investigating, preparing or defending any action, claim,
suit, inquiry, proceeding, investigation or appeal taken from the foregoing by
or before any court or governmental, administrative or other regulatory agency,
body or the SEC or NASD, whether pending or threatened, whether or not such
Indemnified Person is or may be a party thereto ("Indemnified Damages"), to
which any of them may become subject insofar as such Claims (or actions or
proceedings, whether commenced or threatened, in respect thereof) arise out of
or are based upon: (i) any untrue statement or alleged untrue statement of a
material fact in a Registration Statement or any post-effective amendment
thereto or in any filing made in connection with the qualification of the
offering under the securities or other Blue Sky Laws of any jurisdiction in
which Registrable Securities are offered, or the omission or alleged omission to
state a material fact required to be stated therein or necessary to make the
statements therein, in light of the circumstances under which the statements
therein were made, not misleading, (ii) any untrue statement or alleged untrue
statement of a material fact contained in any preliminary prospectus if used
prior to the effective date of such Registration Statement, or contained in the
final prospectus (as amended or supplemented, if the Company files any amendment
thereof or supplement thereto with the SEC) or the omission or alleged omission
to state therein any material fact necessary to make the statements made
therein, in light of the circumstances under which the statements therein were
made, not misleading, (iii) any violation or alleged violation by the Company of
the Securities Act, the Exchange Act, any other law, including, without
limitation, any state securities law, or any rule or regulation thereunder
relating to the offer or sale of the Registrable Securities pursuant to a
Registration Statement, or (iv) any breach of any representation, warranty,
covenant or agreement contained in this Agreement or any document delivered in
connection with this Agreement (the matters in the foregoing clauses (i) through
(iv) being, collectively, "Violations"). The Company shall reimburse the
Investors and each such controlling person, promptly as such expenses are
incurred and are due and payable, for any legal fees or other reasonable
expenses incurred by them in connection with investigating or defending any such
Claim. Notwithstanding anything to the contrary contained herein, the
indemnification agreement contained in this Section 9.1(a): (i) shall not apply
to a Claim arising out of or based upon a Violation which occurs in reliance
upon and in conformity with information furnished in writing to the Company by
any Indemnified Person expressly for use in connection with the preparation of
the Registration Statement or any such amendment thereof or supplement thereto,
if such prospectus was timely made available by the Company; (ii) with respect
to any preliminary prospectus, shall not inure to the benefit of any such person
from whom the person asserting any such Claim purchased the
9
FUEL(TM) PATENT PENDING
Registrable Securities that are the subject thereof (or to the benefit of any
person controlling such person) if the untrue statement or omission of material
fact contained in the preliminary prospectus was corrected in the prospectus, as
then amended or supplemented, if such prospectus was timely made available by
the Company, and the Indemnified Person was promptly advised in writing not to
use the incorrect prospectus prior to the use giving rise to a Violation and
such Indemnified Person, notwithstanding such advice, used it; and (iii) shall
not apply to amounts paid in settlement of any Claim if such settlement is
effected without the prior written consent of the Company, which consent shall
not be unreasonably withheld. Such indemnity shall remain in full force and
effect regardless of any investigation made by or on behalf of the Indemnified
Person and shall survive the transfer of the Registrable Securities by the
Investor.
(b) In connection with any Registration Statement or any amendment or
supplement thereto in which the Investor is participating, the Investor agrees
to indemnify, hold harmless and defend, to the same extent and in the same
manner as is set forth in Section 9.1(a), the Company, each of its directors,
each of its officers who signs the Registration Statement, each Person, if any,
who controls the Company within the meaning of the Securities Act or the
Exchange Act (each, an "Indemnified Party"), against any Claim or Indemnified
Damages to which any of them may become subject, under the Securities Act, the
Exchange Act or otherwise, insofar as such Claim or Indemnified Damages arise
out of or are based upon any (i) Violation, in each case to the extent, and only
to the extent, that such Violation occurs in reliance upon and in conformity
with written information furnished to the Company by such Investor expressly for
use in connection with any Registration Statement covering Registrable
Securities or (ii) the purchase or sale of Common Stock by the Investor pursuant
to the Registration Statement despite the fact that the Investor has received a
Notice of Blocking Period from the Company and has not received notice from the
Company signaling the end of such Blocking Period; and, subject to Section
9.1(c), such Investor will reimburse such Indemnified Parties promptly as such
expenses are incurred and are due and payable for any legal or other expenses
reasonably incurred by them in connection with investigating or defending any
such Claim; provided, however, that the indemnity agreement contained in this
Section 9.1(b) and the agreement with respect to contribution contained in
Section 9.2 shall not apply to amounts paid in settlement of any Claim if such
settlement is effected without the prior written consent of such Investor, which
consent shall not be unreasonably withheld; provided, further, however, that the
Investor shall be liable under this Section 9.1(b) for only that amount of a
Claim or Indemnified Damages as does not exceed the net proceeds to such
Investor as a result of the sale of Registrable Securities pursuant to such
Registration Statement. Such indemnity shall remain in full force and effect
regardless of any investigation made by or on behalf of such Indemnified Party
and shall survive the transfer of the Registrable Securities by the Investor.
Notwithstanding anything to the contrary contained herein, the indemnification
agreement contained in this Section 9.1(b) with respect to any preliminary
prospectus shall not inure to the benefit of any Indemnified Party if the untrue
statement or omission of material fact contained in the preliminary prospectus
was corrected on a timely basis in the prospectus, as then amended or
supplemented.
(c) Promptly after receipt by an Indemnified Person or Indemnified
Party under this Section 9.1 of notice of the commencement of any action or
proceeding (including any governmental action or proceeding) involving a Claim,
such Indemnified Person or Indemnified Party shall, if a Claim in respect
thereof is to be made against any indemnifying party under this Section 9.1,
deliver to the indemnifying party a written notice of the commencement thereof,
and the indemnifying party shall have the right (at its expense) to participate
in, and, to the extent the indemnifying party so desires, jointly with any other
indemnifying party similarly noticed, to assume control of the defense thereof
with counsel mutually satisfactory to the indemnifying party and the Indemnified
Person or the Indemnified Party, as the case may be; provided, however, that
such indemnifying party shall diligently pursue such defense and that an
Indemnified Person or Indemnified Party shall have the right to retain its own
counsel with the fees and expenses to be paid by the indemnifying party, if, in
the reasonable opinion of counsel retained
10
FUEL(TM) PATENT PENDING
by the Indemnified Person or Indemnified Party, as the case may be, the
representation by such counsel of the Indemnified Person or Indemnified Party
and the indemnifying party would be inappropriate due to actual or potential
differing interests between such Indemnified Person or Indemnified Party and any
other party represented by such counsel in such proceeding. The indemnifying
party shall pay reasonable fees for only one separate legal counsel for all
Indemnified Persons or Indemnified Parties (as applicable). The Indemnified
Party or Indemnified Person shall cooperate fully with the indemnifying party in
connection with any negotiation or defense of any such action or claim by the
indemnifying party and shall furnish to the indemnifying party all information
reasonably available to the Indemnified Party or Indemnified Person which
relates to such action or claim. The indemnifying party shall keep the
Indemnified Party or Indemnified Person fully apprised at all times as to the
status of the defense or any settlement negotiations with respect thereto. No
indemnifying party shall be liable for any settlement of any action, claim or
proceeding effected without its written consent, provided, however, that the
indemnifying party shall not unreasonably withhold, delay or condition its
consent. No indemnifying party shall, without the consent of the Indemnified
Party or Indemnified Person, consent to entry of any judgment or enter into any
settlement or other compromise which does not include as an unconditional term
thereof the giving by the claimant or plaintiff to such Indemnified Party or
Indemnified Person of a release from all liability in respect to such claim or
litigation. Following indemnification as provided for hereunder, the
indemnifying party shall be subrogated to all rights of the Indemnified Party or
Indemnified Person with respect to all third parties, firms or corporations
relating to the matter for which indemnification has been made. The failure to
deliver written notice to the indemnifying party within a reasonable time of the
commencement of any such action shall not relieve such indemnifying party of any
liability to the Indemnified Person or Indemnified Party under this Section 9.1,
except to the extent that the indemnifying party is prejudiced in its ability to
defend such action.
(d) The indemnification required by this Section 9.1 shall be made by
periodic payments of the amount thereof during the course of the investigation
or defense, as and when bills are received or Indemnified Damages are incurred.
(e) The indemnity agreements contained herein shall be in addition to
(i) any cause of action or similar right of the Indemnified Party or Indemnified
Person against the indemnifying party or others, and (ii) any liabilities the
indemnifying party may be subject to pursuant to the law.
9.2 Contribution. To the extent any indemnification by an
indemnifying party is prohibited or limited by law, the indemnifying party
agrees to make the maximum contribution with respect to any amounts for which it
would otherwise be liable under Section 9.1 to the fullest extent permitted by
law; provided, however, that: (i) no contribution shall be made under
circumstances where the maker would not have been liable for indemnification
under the fault standards set forth in Section 9.1; (ii) no seller of
Registrable Securities guilty of fraudulent misrepresentation (within the
meaning of Section 10(f) of the Securities Act) shall be entitled to
contribution from any seller of Registrable Securities who was not guilty of
fraudulent misrepresentation; and (iii) contribution by any seller of
Registrable Securities shall be limited in amount to the net amount of proceeds
received by such seller from the sale of such Registrable Securities.
X. GOVERNING LAW; MISCELLANEOUS.
----------------------------
10.1 Governing Law. This Agreement shall be governed by and
interpreted in accordance with the laws of the State of New York without regard
to the principles of conflict of laws.
10.2 Counterparts. This Agreement may be executed in any number of
counterparts, all of which shall be considered one and the same agreement and
shall become effective when counterparts have been signed by each party and
delivered to the other party. In the event any signature
11
FUEL(TM) PATENT PENDING
page is delivered by facsimile transmission, the party using such means of
delivery shall cause four (4) additional original executed signature pages to be
physically delivered to the other party within five (5) days of the execution
and delivery hereof.
10.3 Headings. The headings of this Agreement are for convenience of
reference and shall not form part of, or affect the interpretation of, this
Agreement.
10.4 Severability. If any provision of this Agreement shall be invalid
or unenforceable in any jurisdiction, such invalidity or unenforceability shall
not affect the validity or enforceability of the remainder of this Agreement in
that jurisdiction or the validity or enforceability of any provision of this
Agreement in any other jurisdiction; provided that such severability shall be
ineffective if it materially changes the economic benefit of this Agreement to
any party.
10.5 Survival. The representations, warranties, and agreements of the
parties hereto shall survive each Closing hereunder and the termination of this
Agreement or the Commitment Period. The indemnity and contribution agreements
contained in Sections 9.1 and 9.2 hereof shall survive and remain operative and
in full force and effect regardless of (i) any termination of this Agreement,
(ii) any investigation made by or on behalf of any indemnified party or by or on
behalf of the Company, and (iii) the consummation of the sale or successive
resales of the Common Stock.
10.6 No Third Party Beneficiaries. This Agreement is intended for the
benefit of the parties hereto and their respective permitted successors and
assigns, and is not for the benefit of, nor may any provision hereof be enforced
by, any other person, except as provided in Article IX.
10.7 Further Assurances. Each party shall do and perform, or cause to
be done and performed, all such further acts and things, and shall execute and
deliver all such other agreements, certificates, instruments and documents, as
the other party may reasonably request in order to carry out the intent and
accomplish the purposes of this Agreement and the consummation of the
transactions contemplated hereby.
10.8 Construction. The language used in this Agreement will be deemed
to be the language chosen by the parties to express their mutual intent, and no
rules of strict construction will be applied against any party. Unless the
context of this Agreement otherwise clearly requires, references to the plural
include the singular, the singular the plural and the part the whole and "or"
has the inclusive meaning represented by the phrase "and/or". Unless the context
requires otherwise, (i) any definition of or reference to any agreement,
instrument or other document herein shall be construed as referring to such
agreement, instrument or other document as from time to time amended,
supplemented or otherwise modified (subject to any restrictions on such
amendments, supplements or modifications set forth herein), (ii) any reference
herein to any Person shall be construed to include such Person's successors and
assigns, (iii) the words "herein", "hereof" and "hereunder", and words of
similar import, shall be construed to refer to this Agreement in its entirety
and not to any particular provision hereof, and (iv) all references herein to
Articles, Sections, Exhibits and Schedules shall be construed to refer to
Articles and Sections of, and Exhibits and Schedules to, this Agreement.
10.9 Equitable Relief. The Company recognizes that in the event that
it fails to perform, observe, or discharge any or all of its obligations under
this Agreement, any remedy at law may prove to be inadequate relief to the
Investor. The Company therefore agrees that the Investor shall be entitled to
seek temporary and permanent injunctive relief in any such case without the
necessity of proving actual damages.
12
FUEL(TM) PATENT PENDING
10.10 Consent to Jurisdiction. The parties hereto expressly submit
themselves to the exclusive jurisdiction of the state and federal courts of New
York, New York in any action or proceeding relating to this Agreement or any of
the other documents contemplated hereby or any of the transactions contemplated
hereby or thereby. Each party hereby irrevocably waives, to the fullest extent
permitted by law, any objection that it may now or hereafter have to the laying
of venue of any such action, suit or proceeding brought in such a court and any
claim that any such action, suit or proceeding brought in such a court has been
brought in an inconvenient forum. The parties hereto hereby irrevocably waive
any and all right to a trial by jury with respect to any legal proceeding
arising out of or relating to this Agreement or the transactions contemplated
hereby. The parties hereto irrevocably and unconditionally consent to the
service of process of any of the aforementioned courts in any such action, suit
or proceeding by the mailing of copies thereof by registered or certified mail,
return receipt requested, postage prepaid, at their respective addresses set
forth or provided for herein, such service to become effective ten (10) days
after such mailing. Nothing herein shall affect the right of any party to serve
process in any manner permitted by law or to commence legal proceedings or
otherwise proceed against the other parties in any other jurisdiction.
13
FUEL(TM) PATENT PENDING
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to
be duly executed by their respective authorized officers as of the date hereof.
RAMIUS CAPITAL GROUP, LLC
By: /s/ ▇▇▇▇▇▇ ▇. ▇▇▇▇▇
---------------------------------
Name: ▇▇▇▇▇▇ ▇. ▇▇▇▇▇
Title: Principal
MGI PHARMA, INC.
By: /s/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇
--------------------------------
Name: ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇
Title: CFO
EXECUTION COPY STAND-BY
PURCHASE AGREEMENT
FUEL(TM) PATENT PENDING